Sanofi ADR (SNY)

SNY Chart

Catalysts

News and Press Releases

• 2 Biopharma Stocks Making Big Moves Tuesday

  The Motley Fool | June 20th

  DICESNY
• 2 Bear Market Defying Stocks to Buy in May

  The Motley Fool | May 22nd

  AXSMSNY
• Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

  GlobeNewsWire | May 21st

  REGNSNY
• 5 Things to Know Before Markets Open

  Investopedia | May 19th

  AMGNDEDISSNY
• Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

  GlobeNewsWire | April 26th

  PRVBSNY
• 2 Top Healthcare Stocks Defying the Bear Market

  The Motley Fool | April 7th

  MCKSNY
• Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?

  The Motley Fool | March 30th

  REGNSNY
• PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

  Business Wire | March 29th

  PRVBSNY
• Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

  MarketBeat | March 27th

  REGNSNY
• Regeneron, Sanofi Look for Billions From COPD Drug

  WSJ | March 25th

  REGNSNY
• Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

  CNBC | March 23rd

  REGNSNY
• Regeneron, Sanofi say Dupixent works in COPD

  Market Watch | March 23rd

  REGNSNY
• Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

  GlobeNewsWire | March 23rd

  REGNSNY
• Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

  GlobeNewsWire | March 21st

  REGNSNY
• Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

  GlobeNewsWire | March 18th

  REGNSNY

Company Info